Snapshot

DOI:

Device embolisation during left atrial appendage closure; prognostic value of mitral annular calcification in transcatheter edge-to-edge repair; one-year outcomes of M-TEER in the MiCLASP study and T-TEER in the TriCLASP study; outcomes of coronary sinus reducer from the REDUCER-I study; predictors of target vessel failure post-intravascular lithotripsy; and more

Even if we’re still in midsummer, there is a hint of autumn in this issue, with a selection of the kind of topics you might find at PCR London Valves next November. But that’s not all, as you can see in this issue!

LAA closure device embolisation

In an expert review, Joelle Kefer, Jens Erik Nielsen-Kudsk and colleagues from the European Left Atrial Appendage Closure Club address the management of device embolisation during left atrial appendage closure (LAAC). The authors present strategies for specific LAAC devices in different clinical scenarios, 
as well as techniques ranging from percutaneous recapture to transseptal retrieval.

CT mitral annular calcification and TEER outcomes

Takashi Nagasaka, Raj R. Makkar and colleagues examine whether using pre-procedural computed tomography to visualise and stratify mitral annular calcification can impact procedural success and prognosis. After analysing parameters such as calcium thickness, distribution involvement, and leaflet calcification, the authors found that while severity of mitral annular calcification did not affect all-cause mortality after transcatheter edge-to-edge repair (TEER), calcium thickness >5 mm and leaflet calcification were associated with worse outcomes.

Using the PASCAL system: 1-year outcomes from the MiCLASP study in patients with moderate functional mitral regurgitation

Philipp Lurz, Jorg Hausleiter and colleagues assess whether patients with moderate functional mitral regurgitation might benefit from mitral TEER. In this subanalysis of the 1-year outcomes of the MiCLASP study, patients had sustained clinical, functional and quality-of-life improvements after treatment with the PASCAL transcatheter valve repair system. This article is accompanied by an editorial from Marianna Adamo and Mauro Riccardi.

Using the PASCAL system: 1-year outcomes from the TriCLASP study

Stephan Baldus, Philipp Lurz and colleagues present the 1-year outcomes of the prospective, single-arm, post-market TriCLASP study, in which the PASCAL transcatheter valve repair system was evaluated for treating patients with symptomatic tricuspid regurgitation. Both safety and efficacy were demonstrated. Rebecca T. Hahn contributes an editorial on the evaluation of device therapies for treating tricuspid regurgitation.

One-year results of the REDUCER-I study

In a research correspondence, Stefan Verheye, Shmuel Banai and colleagues discuss the 1-year follow-up results of the REDUCER-I study of patients with refractory angina treated with the coronary sinus Reducer, accompanied by an editorial by Rasha K. Al-Lamee and Michael J. Foley.

Long-term predictors of TVF post-IVL

Reporting on 12-month results from the France LILI registry, Benjamin Honton, Guillaume Cayla and colleagues assess the long-term safety and efficacy of intravascular lithotripsy in a large cohort of all-comer patients treated in routine clinical practice and identify new independent predictors of target vessel failure at 1 year.

Volume 21 Number 15
Aug 4, 2025
Volume 21 Number 15
View full issue

Trending articles
334.7

State-of-the-Art Review

10.4244/EIJ-D-21-00904 Apr 1, 2022
Antiplatelet therapy after percutaneous coronary intervention
Angiolillo D et al
free
84.05

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
45.75

State-of-the-Art

10.4244/EIJ-D-25-01346 May 4, 2026
Slow flow and no reflow after percutaneous coronary intervention
Brugaletta S et al
free
42.15

State-of-the-Art

10.4244/EIJ-D-25-00896 Apr 6, 2026
Pretreatment with antiplatelet agents in patients undergoing coronary revascularisation
Kaur G et al
free
38.2

State-of-the-Art

10.4244/EIJ-D-24-00195 Apr 7, 2025
Percutaneous coronary intervention for calcified and resistant lesions
Pesarini G et al
free
33.5

Original Research

10.4244/EIJ-D-26-00032 May 15, 2026
Glucocorticoids to reduce permanent pacemaker implantation after TAVI: the GLUCO-TAVI randomised trial
Fuertes-Kenneally L et al
32.2

State-of-the-Art

10.4244/EIJ-D-25-00874 Jun 1, 2026
TAVI and coronary interventions: indications, technical considerations, and clinical scenarios
Aquino Bruno H et al
free
29.2

Original Research

10.4244/EIJ-D-25-01370 May 21, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
29.2

Original Research

10.4244/EIJ-D-25-01370 Jun 1, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
X

PCR
Impact factor: 9.2
2025 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2026)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2026 Europa Group - All rights reserved